Lorlatinib is a third-generation new drug for the treatment of non-small cell lung cancer (NSCLC), which has the ability to inhibit anaplastic lymphoma kinase (ALK) and c-ros proto-oncogene 1. (c-ros oncogene 1, ROS1) dual receptor tyrosine kinase (receptor tyrosine kinase, RTK) strong inhibitory effect, for the treatment of patients who have received at least one ALK inhibitor in the past, such as the first-generation ALK inhibitor crizole ALK-positive and (or) ROS1-positive...

【Recommended Dosage】

• Take LORLADX exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking LORLADX unless your healthcare provider tells you to. 

• Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LORLADX if you develop side effects. 

• Swallow LORLADX tablets whole. Do not chew, crush, or split LORLADX tablets. Do not take LORLADX tablets if they are broken, cracked, or not intact. 

• Take LORLADX at approximately the same time each day. 

• You may take LORLADX with or without food. 

• If you miss a dose, take it as soon as you remember. However, if it is close to the time of your next dose (within 4 hours), just take your next dose at your regular time. 

• If you vomit after taking a dose of LORLADX, do not take an extra dose. Take your next dose at your regular time.